Urgently Needed in Korea
Kwangdong Pharmaceutical announced on July 24 that it has signed an exclusive domestic sales and distribution contract with Italy’s rare disease drug specialist Chiesi.
As a result, Kwangdong Pharmaceutical now holds the exclusive domestic sales and distribution rights for three of Chiesi’s rare disease drugs.
The contracted products are the global new drugs Raxone, Elfabrio, and Lamzede, which are used for Leber’s Hereditary Optic Neuropathy, Fabry disease, and Alpha-Mannosidosis respectively.
Raxone is an original drug indicated for Leber’s Hereditary Optic Neuropathy, a rare disease that causes serious vision loss and currently does not have any generics. Kwangdong Pharmaceutical has already completed preparations for domestic distribution of Raxone.
Elfabrio is effective against Fabry disease, a genetic disease that can cause early death from kidney failure, seizures, and heart disease. It is the first product in the same indication group to use plant cell-derived recombinant protein.
Lamzede is the only approved treatment for Alpha-Mannosidosis and was selected as the 5th Global New Drug Urgently Needed in Korea by the Korea National Enterprise for Clinical Trials (KoNECT) in 2022.